Familial ovarian cancer and early ovarian cancer; biologic, pathologic, and clinical features. Int. J. Gynecol. Pathol. 2001; 20:48–63 and
A systematic review and meta-analysis of family history and risk of ovarian cancer. Br. J. Obstet. Gynaecol. 1998; 105:493–9, , , and
Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2000; 9:103–11, , , et al.
Cancer incidence in a population of Jewish women at risk of ovarian cancer. J. Clin. Oncol. 2002; 20:1570–77, , , et al.
Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res. Treat. 2001; 69:101–13 and
Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52:406–14, , , et al.
Secondary primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol. Biomarkers Prev. 2001; 10:995–9, and
Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet. Gynecol. 2000; 95:255–60, , , et al.
Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes Control 2001; 12:713–19, , , and
Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J. Am. Med. Assoc. 2001; 285:1460–65, , , and
A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J. Clin. Epidemiol. 2000; 53:367–75, , and
Menopausal hormone replacement therapy and risk of ovarian cancer. J. Am. Med. Assoc. 2002; 288:334–41, , , et al.
Risk factors for invasive epithelial ovarian cancer: results from a Swedish case–control study. Am. J. Epidemiol. 2002; 156:363–73, , , et al.
Infertility, fertility drugs, and cancer: a pooled analysis of case-control studies. Am. J. Epidemiol. 2002; 155:217–24, , , et al.
Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol. 1996; 88:554–9, , , and
Polycystic ovary syndrome and cancer. Hum. Reprod. Update 2001; 7:522–5
Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa Women's Health Study. Cancer 2002; 94:1612–18, , , et al.
Ovarian and extraovarian endometriosis-associated cancer. Obstet. Gynecol. 2002; 100:788–95, , , , and
Role of endometriosis in cancer and tumor development. Ann. N. Y. Acad. Sci. 2002; 955:281–92
Pelvic inflammatory disease and the risk of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 1996; 5:667–9, , , et al.
Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 1995; 4:447–51, and
Cosmetic talc should not be listed as a carcinogen: comments on NTP's deliberations to list talc as a carcinogen. Regul. Toxicol. Pharmacol. 2002; 36:40–50
Prospective study of talc use and ovarian cancer. J. Natl Cancer Inst. 2000; 92:249–52, , , et al.
Epidemiology of occupational and environmental risk factors related to ovarian cancer. Scand. J. Work Environ. Health 1998; 24:161–4, , , et al.
Patterns of lymph node metastases in clinically unilateral stage I epithelial ovarian carcinoma. Gynecol. Oncol. 2001; 80:56–61, , , et al.
Clinical picture of women with early stage ovarian cancer. Gynecol. Oncol. 1999; 75:476–9, and
Predictive value of normal endovaginal sonography in excluding disease of the female genital organs and adnexa. J. Ultrasound Med. 1994; 13:395–8, , , and
CA125: the past and future. Int. J. Biol. Markers 1998; 13:179–87, , , et al.
Factors influencing serum CA-125 levels in healthy postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2001; 10:489–93, , , et al.
Nongenetic screening of ovarian malignancies. Obstet. Gynecol. Clin. North Am. 2001; 28:637–51,ⅶ
Recruitment strategies in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the first six years. Control. Clin. Trials 2000; 21(6 supp):356–78S, , , et al.
Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353:1207–10, , , et al.
The performance of screening tests for ovarian cancer: results of a systematic review. Br. J. Obstet. Gynecol. 1998; 105:1136–47, and
Osteopontin as a potential diagnostic biomarker for ovarian cancer. J. Am. Med. Assoc. 2002; 287:1671–9, , , et al.
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II: BRCA 1 and BRCA2. J. Am. Med. Assoc. 277:997–1003, , , et al.
Use of CA-125 and ultrasound in high-risk women. Int. J. Gynecol. Cancer 2002; 12:86–91, , , , and
Long-term effects of oral contraceptives on ovarian cancer risk. Int. J. Cancer 2002; 102:262–5, , , et al.
Risk of oral contraceptives in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproduction. Am. J. Epidemiol. 2000; 152:233–41, , , et al.
Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J. Natl Cancer Inst. 2002; 94:32–8, , , and
Prophylactic oophorectomy: reducing the U. S. death rate from epithelial ovarian cancer. A continuing debate. Oncologist 1996; 1:326–30
The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil. Steril. 1987; 47:94–100, and
Bone loss after hysterectomy with ovarian conservation. Obstet. Gynecol. 1995; 86:72–7, , , et al.
Tea consumption and ovarian cancer risk: a case control study in China. Cancer Epidemiol. Biomarkers Prev. 2002; 11:713–18, and
Association of dairy products, lactose, and calcium with risk of ovarian cancer. Am. J. Epidemiol. 2002; 156:148–57, , , et al.
Dietary beta-carotene intake and the risk of epithelial ovarian cancer: a meta-analysis of 3,782 subjects from five observational studies. In Vivo 2001; 15:339–43, and
Carotenoids, antioxidants, and ovarian cancer risk in pre- and postmenopausal women. Int. J. Cancer 2001; 94:128–34, , and
Dietary fibres and ovarian cancer risk. Eur. J. Cancer 2001; 37:2235–9, , , et al.
Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin. Cancer Res. 2002; 8:202–9, , , et al.
Association between acetaminophen or nonsteroidal anti-inflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22:303–9, and
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum 1991; 34:424–5, , and
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J. Med. Genet. 2000; 37:641–5, , , et al.
Health insurance and discrimination concerns and BRCA 1 and 2 testing in a clinic population. Cancer Epidemiol. Biomarkers Prev. 2002; 11:79–87, , , and
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J. Clin. Oncol. 2002; 20:1260–68, , , et al.
Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 2001; 92:959–68, , , et al.
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N. Engl. J. Med. 1998; 339:424–8, , , et al.
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001; 345:235–40, , , et al.
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 2000; 18:2728–32, , , et al.
Prophylactic oophorectomy in carriers of BRCA1 or BRCA 2 mutations. N. Engl. J. Med. 2002; 346:1616–22, , , et al.
Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J. Clin. Oncol. 2002; 20:2092–100, , , and
Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J. Clin. Oncol. 2002; 20:2520–29, , , , and
Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Am. Surg. Oncol. 2000; 7:325–32, , , et al.
Anxiety/uncertainty reduction as a motivation for interest in prophylactic oophorectomy in women with a family history of ovarian cancer. J. Womens Health Gend. Based Med. 2001; 10:189–99, , , and
Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol. Oncol. 2002; 86:212–19, , , et al.
Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2000 May–Jun;10(3): 231–41, , ,